2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Transfusion, Non-Biological Therapies, Devices, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Computer Vision, Machine Learning, Biological Processes, Genomics, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Systems-Based Hematology, Value, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Viral, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Embryo/Fetus, Pediatric, Pregnant, Young Adult
PAPER

1191 Presenting hematologic laboratory values and changes from individualized baseline are associated with subsequent ICU admission in children with sickle cell disease and acute chest syndrome.

Ugochukwu Agbakwuru, MD, MPH, Grace Kalmus, MPH2, Marianne Elaine McPherson Yee, MD, MSc3, Ross M. Fasano I, MD4
1 Emory University School of Medicine, Atlanta, Georgia, United States
2 Children's Healthcare of Atlanta, Atlanta, Georgia, United States
3 Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, United States
4 Emory University School of Medicine, Atlanta, Georgia, United States

INTRODUCTION

Acute chest syndrome (ACS) is the leading cause of death and second most common cause of hospitalization in sickle cell disease (SCD). The clinical course ranges from mild disease to critical illness requiring ICU admission and advanced respiratory support. Although previous studies have largely focused on identifying patients at risk for developing ACS, predictors of severe ACS at initial presentation remain poorly defined.

METHODS

We performed a retrospective cohort study of children aged 0–21 years who developed ACS at presentation or during hospitalization between 01/01/2020 and 12/31/2025 using the Children's Healthcare of Atlanta (CHOA) SCD database. The database is maintained through systematic review of SCD admissions and interfaces with the electronic health record (Epic) to extract laboratory, radiographic, transfusion, and respiratory therapy data. Admissions classified as ACS in the CHOA database underwent radiographic review. Chest radiograph impressions were evaluated using a machine-assisted keyword-based classification algorithm, developed in collaboration with pediatric radiologists and informed by ACS diagnostic guidelines, to identify language supporting ACS. Algorithmically classified studies underwent clinician adjudication to generate a comprehensive cohort of radiographically confirmed ACS admissions, providing a more rigorous cohort than ICD-10 codes or discharge diagnoses alone.

Baseline laboratory values were defined as the average of the 2 most recent steady-state outpatient clinic measurements obtained within <2 years of hospitalization. The primary outcome was ICU admission. Admission laboratory values obtained at emergency department presentation and corresponding changes from individualized baseline were compared between ICU and non-ICU admissions. Continuous variables were compared using the Wilcoxon rank-sum test and categorical variables using Pearson's χ² or Fisher's exact tests, as appropriate.

RESULTS

The cohort included 2,473 ACS admissions among 1,101 unique patients, of which 228 (9.2%) required ICU admission. Compared with non-ICU admissions, children requiring ICU care presented with lower admission hemoglobin (7.8 vs 8.4 g/dL, p<0.001), higher admission reticulocyte count (301 vs 255 ×10⁹/L, p<0.001), higher admission bilirubin (3.0 vs 2.5 mg/dL, p<0.001), higher admission LDH (617 vs 507 U/L, p=0.004), higher admission AST (53 vs 41 U/L, p<0.001), higher admission ALT (24 vs 19 U/L, p<0.001), lower admission platelet count (324 vs 353 ×10⁹/L, p=0.002), higher admission WBC (18 vs 15 ×10⁹/L, p<0.001), and higher admission ANC (13 vs 10 ×10⁹/L, p<0.001).

Relative to individualized baseline, ICU admissions demonstrated a greater median decline from individualized baseline in admission hemoglobin (0.85 vs 0.55 g/dL, p<0.001) and admission platelet count (104 vs 39 ×10⁹/L, p<0.001), and greater median increases from individualized baseline in admission bilirubin (0.65 vs 0.10 mg/dL, p<0.001), admission AST (15 vs 5 U/L, p<0.001), admission WBC (6.3 vs 4.3 ×10⁹/L, p<0.001), and admission ANC (7.3 vs 4.2 ×10⁹/L, p<0.001). No significant differences from individualized baseline were observed for admission reticulocyte count (p=0.90), admission LDH (p=0.20), or admission ALT (p=0.20). Although admission creatinine did not differ significantly between groups (0.39 vs 0.40 mg/dL, p=0.30), an elevated age-adjusted admission creatinine was more common among ICU admissions (8.0% vs 1.2%, p<0.001).

 CONCLUSIONS

Initial admission hematologic laboratory values and changes from individualized baseline are associated with ICU admission in pediatric acute chest syndrome and identify candidate predictors for development of a clinically applicable risk prediction tool. Future studies will incorporate highest respiratory support requirement, infectious pathogen data, and clinical history including prior ACS and ICU admissions into multivariable models to determine the independent predictive value of each variable. If validated, these findings could support development of an evidence-based clinical risk stratification algorithm or a machine learning-based clinical decision support tool capable of rapidly integrating admission laboratory values, individualized baseline data, and relevant clinical history to estimate the severity of an individual ACS admission at initial presentation.

Ugochukwu Agbakwuru, MD, MPH: No relevant conflicts of interest to declare.